A Study to Evaluate the Safety of Aceneuramic Acid Extended Release (Ace-ER; UX001) Tablets in Glucosamine (UDP-N-acetyl)-2-Epimerase (GNE) Myopathy (GNEM) (Also Known as Hereditary Inclusion Body Myopathy [HIBM]) Patients With Severe Ambulatory Impairment

Clinical trial NCT02731690 · TERMINATED

Trial details

NCT number: NCT02731690
Sponsor: Ultragenyx Pharmaceutical Inc
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Hereditary Inclusion Body Myopathy Distal Myopathy With Rimmed Vacuoles Distal Myopathy, Nonaka Type GNE Myopathy Quadriceps Sparing Myopathy Inclusion Body Myopathy 2

Start date: 2016-04-29
Primary completion: 2018-01-10
Enrollment: 42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.